Emeis Stock Falls 3.75% and Slides Among the Biggest Declines of the SBF 120
The healthcare services group's stock drops mid-session, contrary to the bullish movement observed at the end of last week. The stock is among the biggest losers in the SBF 120 in a declining Parisian market, on the eve of a statutory meeting for the group.
The stock falls below its three moving averages and erases its Friday rebound
Emeis loses 3.75% to €13.86 at midday, after having closed at €14.40 on Friday. The session largely erases the 2.5% rebound praised at the end of last week, placing the stock among the biggest declines of the SBF 120, while the index itself is down 0.75% during the session. The price falls below its MM20 (€14.29) and MM50 (€14.36), with a gap of about 3% in both cases. It also just falls below its MM200 at €13.93, 0.5% below, bringing the technical debate back to this medium-term level. The identified support at €13.64 is now immediately within reach of the price. The RSI at 54 remains neutral and does not yet send a signal of exhaustion of the selling pressure.
A general meeting expected on Tuesday, the last short-term calendar marker
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The group's financial calendar highlights the 2026 general meeting, scheduled for June 23, which is tomorrow. This statutory meeting remains a calendar point and not a price driver in itself. Regarding recent performance, the stock has lost 2.19% over the week and 5.39% over the month, while still maintaining a gain of 25.77% over the year. Meanwhile, the market context weighs on the Paris session, in an environment where major central banks have toughened their stance and tensions around the Strait of Hormuz fuel volatility. Nevertheless, the VIX falls nearly 5% to 17.53. In the short term, the maintenance of the support at €13.64 and the behavior of the price around the MM200 at €13.93 will be the levels to watch.
SectorServices et infrastructure de santé›Etablissements de santé / EHPAD
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3 011 millions d'euros
Quarterly revenue: 3 011 millions d'euros
EBITDA: 461 millions d'euros
EBITDA margin: 15,3 %
Net income: -40,4 millions d'euros
Free cash flow: -153 millions d'euros
3 862 millions d'euros
Guidance from the release
First-half performance allows for an upward revision of the 2026 guidance; the trend since the start of the year confirms the continued momentum observed in 2025 and even shows performance that exceeded the Group's initial expectations
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.